强的松治疗纯音阈值正常的急性主观性耳鸣患者的随机对照试验

IF 4.6 2区综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES

iScience Pub Date : 2025-06-09 DOI:10.1016/j.isci.2025.112840

Peifan Li (李沛璠) , Chenhao Che (车晨昊) , Dantong Gu (顾丹彤) , Xiaoling Lu (鲁小玲) , Xiao Xiao (肖潇) , Yanping Yu (俞艳萍) , Dongmei Tang (唐冬梅) , Dan You (尤丹) , Tingting Qian (钱婷婷) , Yongzhen Wu (吴拥真) , Shan Sun (孙珊)

{"title":"强的松治疗纯音阈值正常的急性主观性耳鸣患者的随机对照试验","authors":"Peifan Li (李沛璠) , Chenhao Che (车晨昊) , Dantong Gu (顾丹彤) , Xiaoling Lu (鲁小玲) , Xiao Xiao (肖潇) , Yanping Yu (俞艳萍) , Dongmei Tang (唐冬梅) , Dan You (尤丹) , Tingting Qian (钱婷婷) , Yongzhen Wu (吴拥真) , Shan Sun (孙珊)","doi":"10.1016/j.isci.2025.112840","DOIUrl":null,"url":null,"abstract":"<div><div>The effectiveness of steroid therapy for acute subjective tinnitus (AST) without sudden hearing loss remains controversial. This randomized controlled trial evaluated the effectiveness of short-term oral prednisone (STOP) in patients with AST. The STOP group received a 14-day tapering prednisone for the initial 14 days, and both groups took Ginkgo biloba extract throughout the 3-month follow-up period. The primary outcome was the 12-week change in Tinnitus Handicap Inventory (THI) scores, assessed via intention-to-treat analysis. At the 12-week follow-up, the STOP medication significant reduced THI scores (−27 · 34 [95% CI, −31 · 14 to −23 · 55]) versus control (−15 · 37 [95% CI, −18 · 5 to −12 · 23]), with a mean difference of −11 · 97 points (95% CI, −16 · 85 to −7·09; <em>p</em> < 0 · 0001). Sensitivity analyses and post hoc analyses corroborated these findings. In summary, the STOP treatment plus Ginkgo biloba could effectively lessen the self-reported tinnitus severity in patients with AST.</div></div>","PeriodicalId":342,"journal":{"name":"iScience","volume":"28 7","pages":"Article 112840"},"PeriodicalIF":4.6000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Randomized controlled trial of prednisone in treating acute subjective tinnitus patients with normal pure-tone thresholds\",\"authors\":\"Peifan Li (李沛璠) , Chenhao Che (车晨昊) , Dantong Gu (顾丹彤) , Xiaoling Lu (鲁小玲) , Xiao Xiao (肖潇) , Yanping Yu (俞艳萍) , Dongmei Tang (唐冬梅) , Dan You (尤丹) , Tingting Qian (钱婷婷) , Yongzhen Wu (吴拥真) , Shan Sun (孙珊)\",\"doi\":\"10.1016/j.isci.2025.112840\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The effectiveness of steroid therapy for acute subjective tinnitus (AST) without sudden hearing loss remains controversial. This randomized controlled trial evaluated the effectiveness of short-term oral prednisone (STOP) in patients with AST. The STOP group received a 14-day tapering prednisone for the initial 14 days, and both groups took Ginkgo biloba extract throughout the 3-month follow-up period. The primary outcome was the 12-week change in Tinnitus Handicap Inventory (THI) scores, assessed via intention-to-treat analysis. At the 12-week follow-up, the STOP medication significant reduced THI scores (−27 · 34 [95% CI, −31 · 14 to −23 · 55]) versus control (−15 · 37 [95% CI, −18 · 5 to −12 · 23]), with a mean difference of −11 · 97 points (95% CI, −16 · 85 to −7·09; <em>p</em> < 0 · 0001). Sensitivity analyses and post hoc analyses corroborated these findings. In summary, the STOP treatment plus Ginkgo biloba could effectively lessen the self-reported tinnitus severity in patients with AST.</div></div>\",\"PeriodicalId\":342,\"journal\":{\"name\":\"iScience\",\"volume\":\"28 7\",\"pages\":\"Article 112840\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-06-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"iScience\",\"FirstCategoryId\":\"103\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2589004225011010\",\"RegionNum\":2,\"RegionCategory\":\"综合性期刊\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"iScience","FirstCategoryId":"103","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589004225011010","RegionNum":2,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

摘要

类固醇治疗急性主观性耳鸣（AST）无突发性听力损失的有效性仍然存在争议。这项随机对照试验评估了短期口服强的松（STOP）对AST患者的疗效。STOP组在最初的14天内接受14天逐渐减少的强的松治疗，在3个月的随访期间，两组都服用银杏叶提取物。主要结局是12周耳鸣障碍量表（THI）评分的变化，通过意向治疗分析进行评估。在12周的随访中，STOP药物显著降低了THI评分（- 27.34 [95% CI, - 31.14至- 23.55]），而对照组（- 15.37 [95% CI, - 18.5至- 12.23]），平均差异为- 11.97分(95% CI, - 16.85至- 7.09；p & lt;0.0001)。敏感性分析和事后分析证实了这些发现。综上所述，STOP治疗加银杏叶可有效减轻AST患者自述的耳鸣严重程度。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Randomized controlled trial of prednisone in treating acute subjective tinnitus patients with normal pure-tone thresholds

The effectiveness of steroid therapy for acute subjective tinnitus (AST) without sudden hearing loss remains controversial. This randomized controlled trial evaluated the effectiveness of short-term oral prednisone (STOP) in patients with AST. The STOP group received a 14-day tapering prednisone for the initial 14 days, and both groups took Ginkgo biloba extract throughout the 3-month follow-up period. The primary outcome was the 12-week change in Tinnitus Handicap Inventory (THI) scores, assessed via intention-to-treat analysis. At the 12-week follow-up, the STOP medication significant reduced THI scores (−27 · 34 [95% CI, −31 · 14 to −23 · 55]) versus control (−15 · 37 [95% CI, −18 · 5 to −12 · 23]), with a mean difference of −11 · 97 points (95% CI, −16 · 85 to −7·09; p < 0 · 0001). Sensitivity analyses and post hoc analyses corroborated these findings. In summary, the STOP treatment plus Ginkgo biloba could effectively lessen the self-reported tinnitus severity in patients with AST.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

iScience Multidisciplinary-Multidisciplinary

CiteScore

7.20

自引率

1.70%

发文量

1972

审稿时长

6 weeks

期刊介绍： Science has many big remaining questions. To address them, we will need to work collaboratively and across disciplines. The goal of iScience is to help fuel that type of interdisciplinary thinking. iScience is a new open-access journal from Cell Press that provides a platform for original research in the life, physical, and earth sciences. The primary criterion for publication in iScience is a significant contribution to a relevant field combined with robust results and underlying methodology. The advances appearing in iScience include both fundamental and applied investigations across this interdisciplinary range of topic areas. To support transparency in scientific investigation, we are happy to consider replication studies and papers that describe negative results. We know you want your work to be published quickly and to be widely visible within your community and beyond. With the strong international reputation of Cell Press behind it, publication in iScience will help your work garner the attention and recognition it merits. Like all Cell Press journals, iScience prioritizes rapid publication. Our editorial team pays special attention to high-quality author service and to efficient, clear-cut decisions based on the information available within the manuscript. iScience taps into the expertise across Cell Press journals and selected partners to inform our editorial decisions and help publish your science in a timely and seamless way.